Fly News Breaks for March 2, 2015
REGN
Mar 2, 2015 | 07:49 EDT
RBC Capital believes that recently reported data on Regeneron's Eylea could result in it being used more often, as experts said that the data indicates that the drug should be used as a first option for patients with vision of worse than 20/40, according to the firm. The firm adds that data for a competing drug, RTH258, indicates that it could be effective, but that it has potential safety questions. The firm keeps a $450 price target and Outperform rating on Regeneron.
News For REGN From the Last 2 Days